Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADUS NASDAQ:PGNY NASDAQ:PSNL NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$104.96-1.7%$111.90$88.96▼$136.72$1.96B0.8127,007 shs199,141 shsPGNYProgyny$22.49-4.3%$22.11$13.39▼$27.15$2.02B1.321.01 million shs1.21 million shsPSNLPersonalis$5.39-1.6%$6.06$2.81▼$7.79$484.02M1.861.04 million shs853,203 shsVCYTVeracyte$23.64+0.6%$26.23$19.73▼$47.32$1.84B1.971.97 million shs1.74 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare-1.70%-4.08%-4.90%-0.04%-13.51%PGNYProgyny-4.34%-2.68%+5.89%-3.19%-20.25%PSNLPersonalis-1.64%-16.95%-28.23%+29.57%+56.23%VCYTVeracyte+0.55%-6.38%-14.29%-22.11%-1.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADUSAddus HomeCare4.9388 of 5 stars3.63.00.05.04.02.53.1PGNYProgyny2.0323 of 5 stars2.31.00.00.03.52.51.3PSNLPersonalis3.8577 of 5 stars3.51.00.04.21.92.50.6VCYTVeracyte2.9116 of 5 stars3.40.00.04.34.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADUSAddus HomeCare 3.25Buy$142.5735.83% UpsidePGNYProgyny 2.67Moderate Buy$24.8210.35% UpsidePSNLPersonalis 3.00Buy$7.6742.24% UpsideVCYTVeracyte 2.70Moderate Buy$40.9073.01% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, ADUS, PGNY, and VCYT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025PGNYProgynyTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$24.00 ➝ $27.007/16/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.007/8/2025PGNYProgynyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025PGNYProgynyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$28.006/20/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.006/10/2025ADUSAddus HomeCareMacquarieSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$133.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/12/2025PGNYProgynyCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$23.00 ➝ $21.005/8/2025ADUSAddus HomeCareMacquarieSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$129.00 ➝ $133.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADUSAddus HomeCare$1.15B1.67$5.30 per share19.81$53.52 per share1.96PGNYProgyny$1.17B1.65$0.33 per share68.13$4.96 per share4.53PSNLPersonalis$84.61M5.63N/AN/A$2.87 per share1.88VCYTVeracyte$445.76M4.15$1.04 per share22.67$15.17 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADUSAddus HomeCare$73.60M$4.4323.6919.581.516.52%9.23%6.96%8/4/2025 (Estimated)PGNYProgyny$54.34M$0.5739.4634.602.364.33%10.90%7.20%8/7/2025 (Estimated)PSNLPersonalis-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/5/2025 (Confirmed)VCYTVeracyte$24.14M$0.4157.6632.83N/A7.13%6.14%5.60%8/6/2025 (Estimated)Latest PSNL, ADUS, PGNY, and VCYT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PGNYProgyny$0.42N/AN/AN/A$315.70 millionN/A8/6/2025Q2 2025VCYTVeracyte$0.31N/AN/AN/A$120.90 millionN/A8/5/2025Q2 2025PSNLPersonalis-$0.25N/AN/AN/A$20.12 millionN/A8/4/2025Q2 2025ADUSAddus HomeCare$1.45N/AN/AN/A$345.71 millionN/A5/8/2025Q1 2025PGNYProgyny$0.45$0.17-$0.28$0.17$307.86 million$324.04 million5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/5/2025Q1 2025ADUSAddus HomeCare$1.33$1.42+$0.09$1.16$341.66 million$337.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADUSAddus HomeCareN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADUSAddus HomeCare0.201.741.74PGNYProgynyN/A2.392.39PSNLPersonalisN/A6.916.74VCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADUSAddus HomeCare95.35%PGNYProgyny94.93%PSNLPersonalis61.91%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipADUSAddus HomeCare4.60%PGNYProgyny9.40%PSNLPersonalis3.80%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADUSAddus HomeCare49,70318.40 million17.55 millionOptionablePGNYProgyny31085.72 million77.66 millionOptionablePSNLPersonalis40088.32 million84.97 millionOptionableVCYTVeracyte79078.32 million77.22 millionOptionablePSNL, ADUS, PGNY, and VCYT HeadlinesRecent News About These CompaniesGSA Capital Partners LLP Takes Position in Veracyte, Inc. (NASDAQ:VCYT)August 1 at 5:40 AM | marketbeat.comPicton Mahoney Asset Management Has $7.72 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)July 30 at 4:51 AM | marketbeat.comVeracyte (VCYT) to Release Quarterly Earnings on WednesdayJuly 30 at 4:33 AM | marketbeat.comVictory Capital Management Inc. Purchases 41,248 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 29, 2025 | marketbeat.comVeracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?July 28, 2025 | zacks.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases 22,074 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 28, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Stake Lessened by ARK Investment Management LLCJuly 27, 2025 | marketbeat.comNikko Asset Management Americas Inc. Cuts Stock Position in Veracyte, Inc. (NASDAQ:VCYT)July 27, 2025 | marketbeat.comPinnacle Associates Ltd. Purchases New Stake in Veracyte, Inc. (NASDAQ:VCYT)July 27, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Shares Gap Up - What's Next?July 27, 2025 | americanbankingnews.comVeracyte (VCYT) Soars 7% on S&P SmallCap 600 InclusionJuly 26, 2025 | insidermonkey.comVeracyte (NASDAQ:VCYT) Shares Gap Up - Time to Buy?July 26, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Raised to Buy at Wall Street ZenJuly 26, 2025 | marketbeat.comVeracyte to replace Triumph in S&P SmallCap 600 indexJuly 25, 2025 | msn.comY Intercept Hong Kong Ltd Acquires 24,416 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 24, 2025 | marketbeat.comGW&K Investment Management LLC Raises Stake in Veracyte, Inc. (NASDAQ:VCYT)July 22, 2025 | marketbeat.comJennison Associates LLC Buys 166,605 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 20, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Trading Down 5.9% - Here's WhyJuly 19, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Veracyte, Inc. (NASDAQ:VCYT)July 19, 2025 | marketbeat.comVeracyte Inc (VCYT) Stock Price Down 4.21% on Jul 18July 18, 2025 | gurufocus.comVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSNL, ADUS, PGNY, and VCYT Company DescriptionsAddus HomeCare NASDAQ:ADUS$104.96 -1.82 (-1.70%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$105.01 +0.05 (+0.05%) As of 08/1/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.Progyny NASDAQ:PGNY$22.49 -1.02 (-4.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.24 -0.25 (-1.11%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Personalis NASDAQ:PSNL$5.39 -0.09 (-1.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.34 -0.05 (-0.95%) As of 08/1/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Veracyte NASDAQ:VCYT$23.64 +0.13 (+0.55%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.66 +0.02 (+0.09%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
